who's who

3 Houston innovators to know this week

This week's Houston innovators to know include Nicolaus Radford of Houston Mechatronics Inc. and Sharita M. Humphry and Enrique Castro of BH Ventures. Photos courtesy

Editor's note: This week's roundup of innovators to know in Houston include three self-starting founders — a robotics expert who's job sounds more futuristic that realistic and a duo looking to bridge the gap between Black and Hispanic entrepreneurs while cultivating their business growth.

Nicolaus Radford, CEO, CTO, and co-founder of Houston Mechatronics Inc.

Nicolaus Radford joins the Houston Innovators Podcast to discuss his plans to take his cloud robotics company global. Photo courtesy of HMI

Discussing Nicolaus Radford's career and his current work with his company, Houston Mechatronics Inc., feels like something out of a science fiction movie. But it's real life. HMI is building a fleet of underwater robots, and, before he founded his company in 2014, he worked on humanoid robots for NASA.

Now, there's a growing market need for the type of robots HMI is working on, and he share on the Houston Innovators Podcast that there's a huge international opportunity for him.

"We're absolutely going to be a global company," Radford says, explaining that new clients in these areas are what's calling for the new offices. "The next 12 months of this company are going to be extremely vibrant and dynamic." Read more.

Enrique Castro and Sharita M. Humphry of BH Ventures

Enrique Castro and Sharita M. Humphrey met at an alumni event at UH and decided to work together on an inclusive accelerator program. Courtesy photos

Black and Hispanics tend to fall low on the lists of personal finance and business success, and usually the two communities don't do business together. That's what BH Ventures, a business accelerator program founded by Sharita M. Humphrey and Enrique Castro, is looking to change.

"Enrique and I know that there can sometimes be a barrier between Black and Hispanics doing business together," says Humphrey. "This is why I wanted, as an African American woman, and him, being a Hispanic male, to be able to show that we should be doing business together — especially in the city of Houston."

Humphrey and Castro met at an alumni event for the University of Houston's SURE program, which creates educational programming for entrepreneurs from under-resourced communities. The duo thought that they could create a program that built upon UH's. In February, after building out the curriculum, BH Ventures ran a successful pilot program in collaboration with UH. Read more.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News